



PEPTECH
LIMITED

Peptech Limited • ABN 98 002 951 877
Unit 1, 35 - 41 Waterloo Road
(Locked Bag 2053)
North Ryde NSW 2113
Australia
www.peptech.com
Telephone: +61 2 9870 8788
Facsimile: +61 2 9870 8786

10 February 2005

ASX / MEDIA ANNOUNCEMENT

Peptech appoints new director to drive global profile

Australian biotechnology company, Peptech Limited, has appointed Mr Greg Bundy as a Non-Executive Director. The appointment is part of the company's strategy to expand the mix of skills on the Board with a view to increasing its international presence.

"As part of the strategy to position the company as one of the top five life science companies in Australia, we are looking to increase our profile in the northern hemisphere," said Mr Mel Bridges, Executive Chairman, Peptech Limited.

"The Board feels Mr Bundy's strong global equity market experience, and his network of contacts in the United States and Japan, will be invaluable additions to the Peptech board," he said.

Mr Bridges said the potential for Peptech to play a greater role on the world biotechnology stage was significant in 2005, as investee Domantis moves closer to listing on the NASDAQ, and Peptech considers securing a listing on the London Stock Exchange.

"Mr Bundy's understanding of international commerce will add firepower to the Board's decision-making capability in respect of these events," Mr Bridges said.

Now Sydney-based, Mr Bundy has extensive international business experience gained at the major banking and broking firm, Merrill Lynch.

Mr Bundy said he was delighted to join the Peptech board at a time when the company was clearly positioned to achieve its strategic vision.

"I have reviewed Peptech's aggressive growth strategy and feel privileged to have the opportunity to contribute to implementing it," Mr Bundy said.

"In particular, I feel my international equity experience can add significant value to the Board and to shareholders," he said.

"I believe Peptech's well-stocked product pipeline in both animal and human therapeutics, impressive R&D partners in Domantis and Biosceptre, considerable cash holdings and guaranteed income from royalties, make the company a uniquely attractive investment package for the international biopharmaceutical community," he said.

Mr Bundy started at the New York office of Merrill Lynch in 1984 before becoming Managing Director of the equity division in Tokyo in 1988. He then returned to New York as Managing

Director of international equities in 1992, before accepting the post of Chief Executive Officer for Merrill Lynch in Sydney in 1997.

In early 2000, Mr Bundy also filled the role of Chief Operating Officer for Merrill Lynch Investment Managers in New Jersey. Further, in his capacity as Vice-Chairman of Merrill Lynch's Asia Pacific Region, he was responsible for the firm's institutional broking activities in the region.

Mr Bundy moved on from Merrill Lynch in 2003 to take up a number of independent roles. He currently holds a number of board positions including Chairman of Equity Capital Markets Limited and Chairman of Creatable Media. Mr Bundy has also previously sat on the boards of Photon Group, CPR Group, BBY and BT Funds Management.

Background:

Peptech Limited focuses on the research and development of peptides and proteins in the areas of human pharmaceuticals and animal health. Peptech holds a 36.1 per cent shareholding in Domantis, a UK-based drug development company. The company is positioned to become a globally recognised leader in biopharmaceutical development.

Further information:

Mr Mel Bridges
Executive Chairman
Peptech Limited
Tel: + 61 2 9870 8788
Mobile: 0413 051 600

Dr Paul Schober
Investor Relations
Peptech Limited
Tel: + 61 2 9870 8788